elveInsight’s, “Graft versus host disease Pipeline Insight 2026” report provides comprehensive insights about 45+ Graft Versus Host Disease Companies and 50+ pipeline drugs in Graft versus host disease pipeline landscape. It covers the Graft Versus Host Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Graft versus Host Disease Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Graft versus Host Disease Pipeline? @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight

Key Takeaways from the Graft versus Host Disease Pipeline Report

• On June 01, 2026- Incyte Corporation initiated a phase 3 study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
• On May 29, 2026- Beth Israel Deaconess Medical Center conducted a research study is a way of gaining new knowledge about the treatment of patients with cGVHD. This research study is evaluating a drug called abatacept. Abatacept is a drug that alters and suppresses the immune system. Abatacept is approved by the Food and Drug Administration (FDA) for the treatment of moderate to severe active rheumatoid arthritis in adults and of severe juvenile idiopathic arthritis (JIA) in patients who have failed prior therapy with disease-modifying anti-rheumatic drugs (DMARDs).
• On May 28, 2026- Novartis Pharmaceuticals initiated a study is to assess the efficacy and safety of ruxolitinib in Chinese adult and pediatric participants aged 12 years or older with corticosteroid-refractory chronic graft vs. host disease (SR-cGvHD).
• On May 27, 2026- Sanofi announced a phase 4 study is to verify the pharmacokinetics, efficacy, and safety of belumosudil mesylate tablets in Chinese adolescent participants (aged from 12 to less than 18) with cGVHD who have had an inadequate response to glucocorticoids or other systemic therapies. Participants will receive treatment with belumosudil tablets 200 mg once daily in 28-day cycles during the study.
• On May 26, 2026- Cynata Therapeutics Limited announced a phase II study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD. Severity of GvHD will be assessed at screening and throughout the study using Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines. Eligible subjects will be randomized to receive either CYP-001 IV infusion on Days 0 and 4 or placebo on the same days. All subjects will receive ongoing CS therapy as appropriate per institutional guidelines. Subjects will have study visits up to Day 100 during the Primary Evaluation Period. During the Follow-Up Period, subjects will have study visits up to 24 months.
• DelveInsight’s Graft Versus Host Disease pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Graft Versus Host Disease treatment.
• The leading Graft Versus Host Disease Companies such as Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen and others.
• Promising Graft Versus Host Disease Therapies such as Ibrutinib, Prednisone, ruxolitinib, Axatilimab, GDC-8264, Ruxolitinib, Defibrotide, and others.

Want to know which companies are leading innovation in Graft versus Host Disease? @ Graft versus Host Disease Clinical Trials Assessment

The Graft versus Host Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Graft versus Host Disease Pipeline Report also highlights the unmet needs with respect to the Graft versus Host Disease.

Graft versus Host Disease Overview

Graft versus host disease (GVHD) is a serious complication that occurs when donor immune cells attack the recipient’s body following an allogeneic stem cell or bone marrow transplant. This condition arises because the donor’s immune cells, recognizing the recipient’s cells as foreign, initiate an immune response against them. GVHD primarily involves T-cells from the donor graft and can be classified into two main types: acute and chronic. Acute GVHD typically develops within the first 100 days post-transplant, manifesting through symptoms like skin rashes, jaundice, liver enzyme abnormalities, and diarrhea.

Graft versus host disease Emerging Drugs

• Itolizumab: Equillium

Itolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab was launched in India in 2013 under the brand name ALZUMAB. Itolizumab received emergency use approval in India to treat cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome. The drug is currently in Phase III clinical development for the treatment of acute graft-versus-host disease (aGVHD).

• ABSK021: Abbisko Therapeutics

Pimicotinib (ABSK021), which was independently developed by Abbisko Therapeutics, is a novel, orally administered, highly selective and potent small-molecule inhibitor of CSF-1R. Abbisko is actively exploring the potential of pimicotinib in treating other indications including many types of solid tumors in clinic, and has obtained approval from NMPA to conduct a Phase II clinical study in chronic graft-versus-host disease. Currently, the drug is in the Phase II stage of its development for the treatment of Chronic Graft Versus Host Disease.

• SYN-004: Theriva Biologics

SYN-004 (ribaxamase) is an oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Allogeneic HCT recipients routinely receive long courses of IV beta-lactam antibiotics to treat infection. Antibiotic-mediated damage of the gut microbiome in allogeneic HCT recipients has been strongly associated with adverse outcomes including CDI, vancomycin-resistant enterococci (VRE) colonization and potentially fatal bacteremia and aGVHD. Currently, the drug is in the Phase I/II stage of its development for the treatment of Graft versus host disease.

• SER-155: Seres Therapeutics

SER-155 is an oral, investigational therapeutic comprising a fermented consortium of commensal bacteria, specifically designed to support immunocompromised patients. Its primary mechanism of action involves augmenting crucial microbiome functions that contribute to improved survival and reduced risks of infections and graft versus host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). By leveraging insights from human clinical data, SER-155 aims to fortify the gut microbiome, enhance immune function, and protect against gastrointestinal infections and bacteremia. This multifaceted approach may offer a promising solution for patients facing the challenges of stem cell transplantation. Currently, the drug is in Phase I stage of its clinical trial for the treatment of GvHD.

If you’re tracking ongoing Graft versus Host Disease Clinical trials, this press release is a must-read @ Graft versus Host Disease Treatment Drugs

Graft versus Host Disease Companies

Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen and others.

The Graft versus Host Disease Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Graft versus Host Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graft versus Host Disease Treatment.
• Graft versus Host Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Graft versus Host Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graft versus Host Disease market.

GVHD Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Graft versus host disease products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Graft versus host disease Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Graft versus Host Disease Pipeline Report covers it all @ Graft versus Host Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Graft versus Host Disease Pipeline Report

• Coverage- Global
• Graft versus Host Disease Companies- Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen and others.
• Graft Versus Host Disease Therapies- Ibrutinib, Prednisone, ruxolitinib, Axatilimab, GDC-8264, Ruxolitinib, Defibrotide, and others.
• Graft versus Host Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Graft versus Host Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Graft versus Host Disease treatment landscape in this detailed analysis @ Graft versus Host Disease Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Graft versus host disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Graft versus host disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Itolizumab: Equillium
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ABSK021: Abbisko Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. SER-155: Seres Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Graft versus host disease Key Companies
21. Graft versus host disease Key Products
22. Graft versus host disease- Unmet Needs
23. Graft versus host disease- Market Drivers and Barriers
24. Graft versus host disease- Future Perspectives and Conclusion
25. Graft versus host disease Analyst Views
26. Graft versus host disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight